A new survey of cannabis consumers in the USA debunks some common stereotypes and highlights the diverse demographics of cannabis consumers. The report explores the demographics and motivations behind cannabis use and emphasizes the need for expanded access to a broader range of cannabis products. Despite growing legalization, limited access remains a challenge for many cannabis consumers.
Entrepreneurs entering the cannabis market who believe that typical cannabis consumers are young, long-haired stoners in Hawaiian shirts should reconsider their approach. The latest report from New Frontier Data effectively debunks the stoner stereotype and other misconceptions about cannabis consumers.
The report, “Cannabis Consumers in America: 2023, Part I,” by New Frontier Data, is based on a survey conducted among 5,345 adult Americans (of which 4,358 are cannabis users) in February. The findings indicate that statistically, 42 percent of adult US residents have used THC products and agree that they will likely use them again.
For more news like this, download our free cannabis news app.
As the cannabis survey shows, 39 percent of adult Americans admitted to consuming cannabis in 2022, and an even larger percentage, 42 percent, acknowledged using cannabis in 2023.
The report yielded significant findings regarding cannabis consumers and their motivations:
The survey revealed that doctors recommend the use of medical cannabis for various reasons. In order of popularity, those motivations were:
The frequency of usage among respondents was another reflection of growth. Thirty-one percent of cannabis consumers reported using cannabis multiple times a day, 12 percent once a day, 21 percent multiple times a week, 5 percent once a week, and 11 percent multiple times a month.
Of the 70 percent of current cannabis consumers claiming that their use of cannabis helps them achieve a “specific goal,” that goal increasingly involves relief from various physical ailments and conditions. Fifty-one percent of self-identified medical cannabis consumers in the survey said they had replaced some of their prescription medications with medical cannabis.
Here, CBD (as opposed to THC-rich hemp) often plays a role in pain relief. Fifty-four percent of cannabis consumers said they had tried CBD; even non-consumers of THC-rich hemp (16 percent) had tried these products. The frequency of CBD usage was significant: daily, 17 percent; once to several times a week, 19 percent; once to several times a month, 20 percent; once to several times a year, 26 percent; and once or twice at all, 18 percent for CBD oils. Edibles and skincare products were the most popular.
The report found that, despite the expanding legalization, many cannabis consumers still face limited access to cannabis. Seventy-four percent of American cannabis consumers reside in states with legal access for adult or medical use, as noted by New Frontier Data, but local restrictions and geographical dispersion of dispensaries can pose barriers for cannabis consumers.
“As a result, regulators should work towards ensuring a broader range of cannabis products are available to cannabis consumers,” concludes the report. So far, operators have focused on flower and edible products. Accordingly, it is time for them to expand their product offerings to reach an even larger and new group of cannabis consumers, suggests the report.
—
(Featured image by RDNE Stock project via Pexels)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The DEA has postponed a key hearing on the reclassification of cannabis. The hearing was…
A new California Department of Public Health report has come out with recommendations for THC…
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…